======= PYROXD1 =======
== Gene Information ==
* **Official Symbol**: PYROXD1
* **Official Name**: pyridine nucleotide-disulphide oxidoreductase domain 1
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=79912|79912]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q8WU10|Q8WU10]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PYROXD1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PYROXD1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/617220|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a nuclear-cytoplasmic pyridine nucleotide-disulphide reductase (PNDR). PNDRs are flavoproteins that catalyze the pyridine nucleotide-dependent reduction of thiol residues in other proteins. The encoded protein belongs to the class I pyridine nucleotide-disulphide oxidoreductase family but lacks the C-terminal dimerization domain found in other family members and instead has a C-terminal nitrile reductase domain. It localizes to the nucleus and to striated sarcomeric compartments. Naturally occurring mutations in this gene cause early-onset myopathy with internalized nuclei and myofibrillar disorganization. A pseudogene of this gene has been defined on chromosome 11. [provided by RefSeq, Apr 2017].
* **UniProt Summary**: Involved in cellular response to oxidative stress. {ECO:0000269|PubMed:27745833}.
|Pyr redox 2|
|sarcomere|
|oxidoreductase activity|
|cellular response to oxidative stress|
|response to oxidative stress|
|oxidation-reduction process|
|cellular response to stress|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp136|MS094 2μM R03 exp136]]|-2.95|
|[[:results:exp432|YM155 0.001μM R08 exp432]]|-2.83|
|[[:results:exp125|GSK461364A 0.005μM R03 exp125]]|-2.08|
|[[:results:exp140|Nicotinate 1000μM R03 exp140]]|-2.05|
|[[:results:exp150|SGC0649 7μM R03 exp150]]|-2.02|
|[[:results:exp114|A-196 10μM R03 exp114]]|-1.95|
|[[:results:exp494|Isoniazid 100μM R08 exp494]]|-1.73|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|1.7|
|[[:results:exp214|2-Deoxy-D-glucose 800μM R05 exp214]]|1.71|
|[[:results:exp93|DABN racemic mixture R03 exp93]]|1.73|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|1.88|
|[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|1.89|
|[[:results:exp212|Phenformin 20μM R05 exp212]]|1.93|
|[[:results:exp19|Etoposide 1μM R00 exp19]]|2.09|
|[[:results:exp342|Calcium Ionophore 0.4μM R07 exp342]]|2.1|
|[[:results:exp400|Senexin-A 25μM R07 exp400]]|2.14|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|2.37|
|[[:results:exp191|Hypoxia 5%O2 R04 exp191]]|2.48|
|[[:results:exp94|Nocodazole 0.1μM R03 exp94]]|2.65|
|[[:results:exp22|MLN-4924 2μM R00 exp22]]|2.69|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|2.84|
|[[:results:exp111|R-DABN 8μM R03 exp111]]|2.88|
|[[:results:exp96|BI-2536 0.02μM R03 exp96]]|2.95|
|[[:results:exp126|GSK461364A 0.1μM R03 exp126]]|3.04|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|3.3|
|[[:results:exp98|BI-6727 0.04μM R03 exp98]]|3.33|
|[[:results:exp108|Vinblastine 0.2μM R03 exp108]]|3.35|
^Gene^Correlation^
|[[:human genes:d:ddx1|DDX1]]|0.558|
|[[:human genes:a:atxn10|ATXN10]]|0.512|
|[[:human genes:t:thg1l|THG1L]]|0.51|
|[[:human genes:t:tsen34|TSEN34]]|0.506|
|[[:human genes:e:elp2|ELP2]]|0.505|
|[[:human genes:d:dpagt1|DPAGT1]]|0.492|
|[[:human genes:c:c14orf166|C14orf166]]|0.49|
|[[:human genes:t:tsen54|TSEN54]]|0.485|
|[[:human genes:v:vezt|VEZT]]|0.472|
|[[:human genes:r:rtcb|RTCB]]|0.471|
|[[:human genes:r:rfk|RFK]]|0.464|
|[[:human genes:a:atic|ATIC]]|0.454|
|[[:human genes:d:ddx39a|DDX39A]]|0.451|
|[[:human genes:a:alg1|ALG1]]|0.449|
|[[:human genes:u:uap1|UAP1]]|0.446|
|[[:human genes:p:pmm2|PMM2]]|0.442|
|[[:human genes:f:fh|FH]]|0.441|
|[[:human genes:f:fam98b|FAM98B]]|0.439|
|[[:human genes:d:dolk|DOLK]]|0.42|
|[[:human genes:e:eef1e1|EEF1E1]]|0.418|
|[[:human genes:e:elp3|ELP3]]|0.418|
|[[:human genes:g:gemin6|GEMIN6]]|0.412|
|[[:human genes:p:pelo|PELO]]|0.411|
|[[:human genes:u:urm1|URM1]]|0.41|
|[[:human genes:t:triap1|TRIAP1]]|0.403|
|[[:human genes:r:rft1|RFT1]]|0.402|
|[[:human genes:g:gfpt1|GFPT1]]|0.401|
Global Fraction of Cell Lines Where Essential: 346/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|15/28|
|blood|9/28|
|bone|10/26|
|breast|13/33|
|central nervous system|33/56|
|cervix|1/4|
|colorectal|8/17|
|esophagus|7/13|
|fibroblast|1/1|
|gastric|8/16|
|kidney|9/21|
|liver|11/20|
|lung|33/75|
|lymphocyte|3/16|
|ovary|14/26|
|pancreas|15/24|
|peripheral nervous system|1/16|
|plasma cell|2/15|
|prostate|1/1|
|skin|13/24|
|soft tissue|5/9|
|thyroid|1/2|
|upper aerodigestive|15/22|
|urinary tract|15/29|
|uterus|2/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 107
* **Expression level (log2 read counts)**: 4.76
{{:chemogenomics:nalm6 dist.png?nolink |}}